Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis (JTA-KOA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04333160
Recruitment Status : Recruiting
First Posted : April 3, 2020
Last Update Posted : April 3, 2020
Sponsor:
Collaborator:
Nordic Bioscience A/S
Information provided by (Responsible Party):
Bone Therapeutics S.A

Brief Summary:

Osteoarthritis is a degenerative, chronic, and progressive joint disease considered as the most common joint disorder worldwide. In healthy joints, there is a continuous process of natural breakdown and repair of cartilage. This process becomes disrupted in OA, leading to degeneration and loss of articular cartilage, along with other joint changes, including subchondral bone remodeling, osteophyte formation, thickening of the capsule and sometimes inflammation of the synovia. JTA-004 is a plasma protein solution supplemented with HA and clonidine developed as a single IA injection for the treatment of knee OA. Local administration of JTA-004 into the joint cavity is intended to relieve chronic pain in subjects suffering from knee OA and discomfort associated with the IA administration.

The JTA-004 Phase III study is a placebo and active-controlled, randomized, double-blind study to evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee at 3 months compared to placebo or active comparator. The study is expected to enrol 676 patients with mild to moderate symptomatic knee osteoarthritis in 22 centres in 6 European countries and Hong Kong SAR.


Condition or disease Intervention/treatment Phase
Symptomatic Osteoarthritis of the Knee With Kellgren-Lawrence Grade II and III Drug: JTA-004 Device: Hylan G-F 20 Other: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 676 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis
Actual Study Start Date : March 10, 2020
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : October 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: JTA-004
single knee intra-articular injection of JTA-004 solution (2ml)
Drug: JTA-004
Patients will undergo a single intra-articular injection of JTA-004 into the knee joint

Placebo Comparator: placebo
single knee intra-articular injection of saline solution (2ml)
Other: placebo
Patients will undergo a single intra-articular injection of placebo into the knee joint
Other Name: saline solution

Active Comparator: Hylan G-F 20
single knee intra-articular injection of Hylan G-F 20 (6ml)
Device: Hylan G-F 20
Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint




Primary Outcome Measures :
  1. knee pain [ Time Frame: 3 months ]
    Difference between JTA-004 and placebo in mean change from baseline in knee pain at Month 3 using the Western Ontario McMaster University (WOMAC®) VA3.1 pain subscale (subscale A).


Secondary Outcome Measures :
  1. knee pain [ Time Frame: 6 months ]
    Difference between JTA-004 and placebo in mean change from baseline in knee pain at Month 6 using the WOMAC® VA3.1 pain subscale (subscale A)

  2. Knee pain [ Time Frame: 3 months ]
    Difference between JTA-004 and active comparator in mean change from baseline in knee pain at Month 3 using the WOMAC® VA3.1 pain subscale (subscale A)

  3. knee physical function [ Time Frame: 3 months ]
    Difference between JTA-004 and placebo in mean change from baseline in knee physical function at Month 3 using the WOMAC® VA3.1 physical function subscale (subscale C)

  4. Patient Global assessment [ Time Frame: 3 months ]
    Difference between JTA-004 and placebo in mean change from baseline in PGA at Month 3

  5. physical function [ Time Frame: 6 months ]
    Difference between JTA-004 and placebo in mean change from baseline in knee physical function at Month 6 using the WOMAC® VA3.1 physical function subscale (subscale C)

  6. subject global health and well-being [ Time Frame: 3 months ]
    Difference between JTA-004 and placebo in mean change from baseline in subject global health and well-being score at Month 3 using the EQ-5D-5L questionnaire

  7. responder rate [ Time Frame: 3 months ]
    - Difference between JTA-004 and placebo in responder rate (defined as ≥ 30% pain intensity reduction) at Month 3



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ambulatory (able to walk unassisted, the use of a crutch or a walking stick (only one) is allowed if already used at screening but should be avoided during the study up to the 6-month follow-up visit)
  • Diagnosed with primary knee OA, fulfilling the following American College of Rheumatology (ACR) criteria at the target knee:

    • Pain present for most days of the preceding month
    • Morning stiffness < 30 minutes
    • Kellgren-Lawrence grade II or III (confirmed by appropriate X-rays taken within 6 months prior to screening visit)
  • Target knee pain ≥ 40 mm and ≤ 80 mm on a 0-100 mm visual analogue scale (VAS) (pain during the last 48 hours) at screening and baseline Insufficient/failed response or intolerance to analgesics and/or non-steroidal anti-inflammatory drugs (NSAIDs) as reported by the subject
  • Willing and able to abstain from initiation of physical therapy and of use of knee braces at the target knee up to the 6-month follow-up visit (a subject undergoing physical therapy or using knee braces at a stable frequency for at least 2 weeks prior to screening is allowed to continue at same frequency (frequency increase is not allowed))
  • Capable to understand and comply with study requirements and to provide a written, dated, and signed informed consent prior to any study procedure for participation in the study and transmission of personal "pseudo-anonymized" data

Exclusion Criteria:

  1. History of trauma or surgery or arthroscopy at the target knee within 12 months before inclusion
  2. Concomitant inflammatory disease or other conditions affecting the joints (e.g., infectious arthritis, rheumatoid arthritis, psoriatic arthritis or spondyloarthropathy, Paget's disease, hemochromatosis…)
  3. Any target knee abnormality that could impact safety or efficacy assessment
  4. Microcrystalline arthropathies: chondrocalcinosis/calcium pyrophosphate dihydrate disease (pseudo-gout) or gout if believed likely to interfere with the study endpoints, in the opinion of the Investigator
  5. Clinically significant valgus/varus deformities at the Investigator's discretion
  6. Any musculoskeletal condition (such as symptomatic hip OA, amputation, neurologic disorder, chronic back pain with or without radiculopathy, sciatica) that would impede measurement of efficacy at target knee
  7. Contralateral knee pain equal to or exceeding the pain in the target knee (on a 0-100 mm VAS during the last 48 hours) at screening and/or baseline
  8. Knee arthroplasty planned within 12 months after the screening visit Current or previous diagnoses, signs and/or symptoms
  9. Uncontrolled diabetes mellitus (hemoglobin A1c [HbA1c] > 10% or > 86 mmol/mol), end-stage hepatic or renal disease (severe and clinically significant abnormalities according to local laboratory ranges) documented in the subject's file
  10. Any relevant cardiovascular disease (severe coronary insufficiency, conduction disturbances, recent myocardial infarction, cerebrovascular disease) or any clinically significant electrocardiogram (ECG) abnormality as judged by the Investigator
  11. Subject with neuropathic pain or chronic pain syndrome including fibromyalgia
  12. Current (or within the last 5 years prior to entering the study) history of solid or hematological neoplasia or bone marrow transplantation (except for basal cell carcinoma and completely excised squamous cell carcinoma)
  13. Other severe acute or chronic medical or psychiatric conditions or pre-dispositions or laboratory abnormalities, as judged by the Investigator
  14. Current or past history of coagulation disorders (according to local laboratory ranges), as judged by the Investigator
  15. Hypersensitivity to any components of hyaluronic acid (HA)-based injection products
  16. Hypersensitivity to human biological material including blood and blood-derived products, potential excipients and residues from manufacturing process, documented clinically or by laboratory tests
  17. Hypersensitivity to avian proteins Current or previous treatment
  18. Participation in another clinical trial within 3 months prior to screening (within 1 year prior to screening if disease-modifying OA drug (DMOAD) received and if the Investigator considers it could impact the safety or efficacy assessment)
  19. Subject previously treated with JTA-004 within 2 years prior to screening
  20. Subject treated with intra-articular viscosupplement or blood-derived product (e.g., platelet-rich plasma) injection in the target knee within 6 months prior to screening
  21. Subject treated with intra-articular glucocorticoid injection in the target knee within 4 months prior to screening
  22. Subject having started the use of slow acting drugs for OA such as glucosamine, glucosamine sulfate, chondroitin sulfate, diacerein, curcumin, soybean/avocado extracts or related products within 1 month prior to screening
  23. Current chemo-, radio- or immuno-cancer-therapy or immunosuppressive therapy
  24. Chronic (≥ 3 days/week within the last 3 months) use of opioids other than weak opioids (such as codeine, dihydrocodeine, tramadol…)
  25. Chronic (> 15 consecutive days) use of systemic steroids Safety aspects concerning female subjects of childbearing potential
  26. Breast-feeding
  27. Pregnancy
  28. Woman with positive pregnancy test
  29. Woman not willing or not able to use a highly effective contraceptive method during the 6-month active follow-up period. Highly effective birth control methods are:

    1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    3. Intrauterine device
    4. Intrauterine hormone-releasing system
    5. Bilateral tubal occlusion Other exclusion criteria
  30. Body Mass Index (BMI) of 40 kg/m2 or greater
  31. Signs of an active drug or alcohol dependence, serious current illness, mental illness or any other factors which may interfere with subject's ability to understand and comply with study requirements, as judged by the Investigator
  32. Life expectancy less than 12 months at screenin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04333160


Contacts
Layout table for location contacts
Contact: Olivier Godeaux, MD +32 71 12.10.00 clinicaltrials@bonetherapeutics.com

Locations
Layout table for location information
Denmark
The Parker Institute Recruiting
Frederiksberg, Denmark, 2000
Contact: study coordinator    +45 3816 4158      
Sanos Clinic Recruiting
Herlev, Denmark, 2730
Contact: study coordinator    +45 7370 8200      
Sanos Clinic Recruiting
Vejle, Denmark, 7100
Contact: study coordinator    +45 4057 3307      
Sponsors and Collaborators
Bone Therapeutics S.A
Nordic Bioscience A/S
Layout table for additonal information
Responsible Party: Bone Therapeutics S.A
ClinicalTrials.gov Identifier: NCT04333160    
Other Study ID Numbers: 000014/BT
First Posted: April 3, 2020    Key Record Dates
Last Update Posted: April 3, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hylan
Viscosupplements
Protective Agents
Physiological Effects of Drugs